Nu-3 (cDFU)
Nu-3 (Mucositis)
Nu-8 (cUTI)
Nu-8 (Cystic Fibrosis)
Posters & Publications
26 May Lakewood-Amedex Inc. Appoints Chief Medical Officer And Chief Scientific Officer To Enhance Drug Development And Clinical Trials Programs
Posted at 06:33h in Press Releases
SARASOTA, Fla., May 26, 2016 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has appointed Steve Miley, M.D., to serve as its Chief Medical Officer. Dr. Miley, currently a practicing physician and a member of the Company's...
19 May Lakewood-Amedex Announces Its Novel Bisphospocin® Class Of Antimicrobials Kills Multidrug Resistant-Tuberculosis (MDR-TB) Strains In Fifteen Minutes
SARASOTA, Fla., May 19, 2015 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven...
12 Mar Lakewood-Amedex Announces Expanded Research Collaboration With The University Of Jyvaskyla Following Promising Results Demonstrating Bisphosphocin™ Activity Against Borrelia Burgdorferi
SARASOTA, Fla., March 12, 2015 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has expanded upon a research collaboration with Dr. Leona Gilbert at the Department of Biological and Environmental Sciences of the University of Jyvaskyla, Finland to...
11 Dec Lakewood-Amedex Submits Investigational New Drug Application for Bisphosphocin™ Nu-3 for the Treatment of Diabetic Foot Infections
SARASOTA, Fla., Dec. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced that the Company has submitted an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to conduct a Phase 1/2a study of Nu-3 as a...
11 Sep Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology
SARASOTA, Fla., Sept. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued a 'Notice of Allowance' for patent application 11/673,486 entitled 'Oligonucleotide-Containing Pharmacological Compositions And Their Uses'. The...
18 Jun Lakewood-Amedex Raises $5.5 Million In Series C Preferred Stock Financing
SARASOTA, Fla., June 18, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has raised a total of $5.5 million, before fees and expenses, through a Series C Preferred stock offering from a group of accredited investors. ...
08 Jan Lakewood-Amedex Inc. Appoints Geoffrey F. Cox To Its Board Of Directors
SARASOTA, Fla., Jan. 8, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Geoffrey F. Cox, Ph.D., to serve on its board of directors. Dr. Cox, currently an independent consultant to the Biotechnology and Life...
09 Oct Lakewood-Amedex Signs Strategic Advisory Agreement With H.C. Wainwright & Co.
SARASOTA, Fla., Oct. 9, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has entered into a strategic advisory agreement with H.C. Wainwright & Co., LLC ("Wainwright"). Pursuant to this agreement, Wainwright will assist Lakewood-Amedex in exploring various licensing,...
10 Sep Lakewood-Amedex to Present Data on Bisphosphocin™ Nu-3 Bacteriacidal Effect on Bacteria Established in Biofilm at the ICAAC Conference
SARASOTA, Fla., Sept. 10, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that in vitro studies demonstrate that its bisphosphocin class of antimicrobials is highly effective at killing bacteria established in biofilm. The results will be presented in...
31 Jul Lakewood-Amedex Announces Its Novel Bisphosphocin Class Of Antimicrobials Are Active Against NDM-1 Positive Bacterial Strains
SARASOTA, Fla., July 31, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by ImQuest BioSciences of Fredrick, MD, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven...
Leveraging next-generation
antimicrobials to address significant
unmet medical needs in the treatment
of serious infectious diseases,
improving patient outcomes and
significantly reducing the urgent
threats posed by increasingly
antibiotic-resistant bacterial strains.
Lakewood-Amedex Inc.
8031 Cooper Creek Blvd., Unit 103
University Park, FL 34201
LAKEWOOD-AMEDEX ENROLLS FIRST PATIENT IN PHASE 2 CLINICAL TRIAL FOR PATIENTS WITH CHRONIC DIABETIC FOOT ULCERS (cDFU) April 5, 2022
LAKEWOOD-AMEDEX APPOINTS TWO NEW BOARD MEMBERS January 25, 2022
LAKEWOOD-AMEDEX APPOINTS CHIEF MEDICAL OFFICER AND ADDS NEW MANAGEMENT TEAM MEMBERS January 19, 2022
Lakewood-Amedex, Inc. Copyright 2022 – All Rights Reserved